Designer Drugs
Out of context: Reply #397
- Started
- Last post
- 451 Responses
- yuekit0
https://neo.life/2020/10/inside-…
There’s no question that the psychedelic renaissance is in full bloom. After a decades-long battle to push through regulatory barriers and overcome long-enduring stigmas, psychedelics are poised to cross the threshold into a post-prohibition future of FDA approval, legalization, and a thriving biotech industry.
To investors, psychedelics are increasingly looking like a good bet. Last month, the psychedelic renaissance reached a new milestone when Compass Pathways, a London-based psilocybin research and therapy company, became the first psychedelic company to go public—receiving a post-IPO run-up valuation of $1.1 billion. Compass (which received seed investment from Peter Thiel’s Thiel Capital) was granted Breakthrough Therapy designation from the FDA for COMP360, a new method for the large-scale production of synthetic psilocybin. The company is currently conducting an FDA Phase 2b clinical trial of psilocybin therapy for treatment-resistant depression, with results expected in 2021.